Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.

Subjects with mild cognitive impairment are at increased risk to develop Alzheimer’s disease (AD) type dementia. Abnormal levels of beta-amyloid and tau in the cerebrospinal fluid (CSF) and medial temporal lobe atrophy on MRI are biomarkers that can predict AD-type dementia. With this study we investigated how those CSF and MRI biomarkers can best be combined to predict progression to AD-type dementia in subjects with MCI. We found that when MRI was tested first, the CSF biomarkers increased predictive accuracy for progression to AD-type dementia in the next two years, regardless of the findings on MRI. When CSF was tested first, MRI further increased predictive accuracy in subjects with normal CSF but not in subjects with abnormal CSF.

>>> Click here for scientific abstract